Loading...
XNAS
PCRX
Market cap1.43bUSD
Oct 08, Last price  
36.39USD
1D
44.40%
1Q
42.82%
Jan 2017
12.66%
IPO
417.64%
Name

Pacira Biosciences Inc

Chart & performance

D1W1MN
XNAS:PCRX chart
P/E
203.50
P/S
1.97
EPS
0.18
Div yield, %
—
Shrs. gr., 5y
0.62%
Rev. gr., 5y
11.07%
Revenues
726m
+3.63%
13,925,00015,006,00014,562,00015,689,00039,084,00085,551,000197,668,000248,997,000276,371,000286,630,000337,277,000421,026,000429,647,000541,533,000666,823,000674,978,000700,966,000726,411,000
Net income
7m
P
-41,862,000-31,707,000-27,149,000-43,328,000-52,281,000-63,909,000-13,716,0001,856,000-37,949,000-42,611,000-471,000-11,016,000145,523,00041,980,00015,909,00041,955,000-99,560,0007,034,000
CFO
152m
-19.75%
-29,189,000-20,838,000-24,880,000-31,000,000-70,130,000-43,216,00025,469,00028,996,00033,453,00017,785,00048,870,00070,520,00077,032,000125,717,000145,274,000154,649,000189,389,000151,994,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.

Key people

Independent Chairman of the Board · since 2025
Chief Executive Officer, Director · since 2024
Shawn Cross
Chief Financial Officer · since 2024
Daryl Gaugler
Executive Vice President - Commercial Operations · since 2025
Lauren Riker
Senior Vice President - Finance, Principal Accounting Officer · since 2024
Kristen Williams
Chief Administrative Officer, Secretary · since 2014
Krys Corbett
Chief Business Officer · since 2025
Jonathan Slonin
Chief Medical Officer · since 2023
Brendan Teehan
Chief Commercial Officer · since 2025
Marcelo Bigal
Independent Director · since 2023
Independent Director · since 2023
Christopher Christie
Independent Director · since 2022
Mark Froimson
Independent Director · since 2018
Independent Director · since 2026
Mark Kronenfeld
Independent Director · since 2013
Independent Director · since 2023
Alethia Young
Independent Director · since 2023
IPO date
Feb 03, 2011
Employees
715
Domiciled in
US
Incorporated in
US
Legal address
C/O The Corporation Trust Company
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Headquarters
5401 West Kennedy Boulevard
Suite 890
Tampa, FL 33609
US
Previous name
Pacira Pharmaceuticals, Inc

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT